The effects of a chronic aluminum (Al) exposure on biliary secretory function, with special emphasis on hepatic handling of non-bile salt organic anions, was investigated. Male, Wistar rats received intraperitoneally either 27 mg per Kg of body weight of Al -as Al hydroxide-[Al (+) rats] -or the vehicle (saline) [Al (-) rats], thrice a week, for 3 months. Serum and hepatic Al levels were increased by the treatment (~ 9 and 4 folds, respectively). This was associated with enhanced malondialdehyde formation (+110%), and reduction in GSH content (-17%) and in the activity of the antioxidant enzymes, catalase (-84%), and GSH-peroxidase (-46%). Bile flow (-23%) and the biliary output of bile salts (-39%), cholesterol (-43%) and proteins (-38%) were decreased as well. Compartmental analysis of the plasma decay of the model organic anion, bromosulphophthalein revealed that sinusoidal uptake and canalicular excretion of the dye were significantly decreased in Al (+) rats (-53% and -43%, respectively).
INTRODUCTION
Aluminum (Al) is one of the most abundant metals in the earth crust. Human exposure to Al has been increasing during the last decades. This element appears mainly in food products and in drinking water derived from both natural sources and treatment methods (Yokel and McNamara, 2001) . The major contributors to the current human exposure are food products such as grain products, processed cheese, and salt (Nieboer et al., 1995) . In addition, pharmaceutical products and medical treatments can be an important way to incorporate high levels of Al, either as an active compound or as a contaminant. For example, Al hydroxide is used as antiacid and as phosphate binder in vaccines, and antiperspirant use has been shown to contribute significantly to Al bioavailability (Yokel and McNamara, 2001 ). Finally, bioavailability by inhalation of airborne soluble Al was shown to be about 1.5% in the industrial environment (Yokel and McNamara, 2001 ).
Al has the potential to be toxic for humans. Patients on dialysis (Alfrey et al., 1976) or on long-term treatment with total parenteral nutrition (Klein, 1993) have been shown to accumulate this metal in different organs. The human toxicological effects include encephalopathy (Alfrey et al., 1976) , bone disease (Ward et al., 1978) and anemia (Short et al., 1980) . Finally, Al is a possible contributing factor in Alzheimer's disease (Campbell, 2002) .
studied as yet. However, they can be considerably different from those occurring under short-term exposure, since exacerbation of the deleterious effect due to hepatic accumulation of Al or other potentially toxic biliary constituents or, conversely, compensatory mechanisms may occur. Therefore, we have investigated here, in the rat model, the interaction between chronic exposure to Al and bile secretory function, with special emphasis on organic anion biliary transport.
Bile formation and biliary excretion of cholephilic xenobiotics is determined by the ability of the hepatocyte to transport solutes. Several transport systems have been identified both in the sinusoidal and in the canalicular membranes, and most of them have been functionally characterized by molecular cloning (Jansen, 2000) . The Mrp2 (multidrug resistance-associated protein), located in the canalicular membrane, mediates the rate-limiting step in the biliary secretion of different organic anions, including glutathione (GSH)-S-conjugates of, for example, leukotriene-C4 or bromosulphophthalein (BSP), glucuronide conjugates of bilirubin and estrogens and bile salts, and both reduced and oxidized GSH (Konig et al., 1999; Paulusma et al., 1999) . Excretion of the last two compounds has been shown to be a driving force for the so called "bile salt-independent fraction of the bile flow" (Ballatori and Truong, 1992) . Therefore, our second aim was to investigate the functional status of Mrp2, due to its dual, key role both in the generation of bile flow and in the biliary transport of organic anions. 
Oxidative stress measurement
The amount of aldehydic products generated by lipid peroxidation in liver tissue was quantified by the thiobarbituric acid (TBA)-reacting substances (TBARS) colorimetric method of Ohkawa et al. (1979) . The colored products resulting from the reaction between TBA and the hydrolyzed, peroxidized lipids were extracted with nbutanol, and the color measured at 532 nm. TBARS were expressed in terms of malondialdehyde (MDA) levels as nmoles per g of liver weight, by using a standard curve of 1,1,3,3-tetramethoxypropane, which is converted mole for mole into MDA.
Liver homogenates in 5% TCA were used to measure total GSH levels, as the main non-protein sulphidryl compounds, according to the method of Ellman et al. (1959) . Glutathione S-transferase (GST), catalase (CAT) and glutathione peroxidase (GSH-Px) activities were assessed in liver cytosolic fractions. The cytosol fraction was obtained by ultracentrifugation (100,000 x g) of liver homogenates (20 %, w/v) prepared in 1mM EDTA, 30 mM Na 2 HPO 4 and 250 mM sucrose buffer, pH 7.4. GST activity was assayed using 1-chloro-2,4-dinitrobenzene (CDNB) as substrate (Goldstein and Combes, 1966) , and expressed as nmol/min per mg of protein. CAT and GSH-Px activities were assessed by the method of Beers and Sizer (1952) and Paglia and Valentine (1967) , respectively. Protein levels in each fraction were determined by the method of Lowry et al. (1951) .
Basal bile flow and pharmacokinetic studies
At 90 days of treatment, was anaesthetized with acepromazine (1 mg per Kg of body weight, ip) and ketamine (100 mg per Kg of body weight, ip). The bile duct and the right femoral vein were cannulated with polyethylene tubing PE 10 and PE 50, respectively. Body temperature was maintained throughout at 37 ± 0.5°C with a heating lamp, to avoid hypothermic variations of bile secretory function. After 20 minutes of stabilization, spontaneously secreted bile was collected for 15 min in preweighed vials and on ice. Bile flow was determined gravimetrically, by assuming a bile density of 1g/ml, and expressed as µl/min per 100 g of body weight. Biliary excretion outputs were calculated as the product of bile flow and solute concentration values.
After these basal studies, pharmacokinetic studies were carried out to characterized the functional status of the non-bile salt organic anion transport systems, by using the Mrp2 substrate, BSP. For this purpose, rats of both groups received an iv injection of 6 mg per 100 g body weight of BSP. Blood samples were collected every 2 min during 30 min, and bile samples were collected every 10 min, for 60 min.
Plasma and bile BSP concentrations were determined spectrophotometrically at 580 nm, after addition of 0.5 M NaOH. The percentage of biliary BSP recovery was estimated by the percent ratio between the dye excreted in bile samples throughout the experimental period and the amount of BSP injected.
In vivo pharmacokinetic studies of BSP plasma decay were carried out to assess the fractional transfer rates for the transport of the dye from plasma to liver (hepatic uptake; r 12 ), liver to plasma (sinusoidal efflux; r 21 ) and liver to bile (canalicular excretion; r 3 ), and other pharmacokinetic parameters. For this purpose, the plasma dye concentration data (C p ), plotted against time (t), were fitted by a least-squares curve-fitting technique to the following biexponential equation: Volume of distribution of the dye is given by:
where D is the dose of BSP administered.
Plasma clearance (Cl p ) was calculated as follows:
where AUC the area under the curve, which can be calculated as:
Half-times for the rapid (t 1/2 ) and the slow (t 1/2 ß) phases of BSP plasma decay were calculated as follows:
The fractional transfer rates were calculated as previously described by Richards et al. (1959) 
Free and GSH-conjugated BSP (GSH-BSP) were separated from each other by reverse-phase high-performance thin-layer chromatography (RP-HPTLC), by adapting the method for HPLC of Snel et al. (1993) . Briefly, samples and standards (BSP and GSH-BSP) (<1 µL) were spotted on RP-HPTLC plates (Sigma-Aldrich, Mo, USA). The mobile phase consisted of 10 mM sodium phosphate buffer, pH 6: acetonitrile (80:30, v:v) . Chromatography was carried out with an Eastman Chromagram chamber plate set (Distillation Products Industries, Rochester, NY). After one hour, bands were visualized under NH 3 atmosphere and immediately digitized. Densitometry of resulting bands was performed by image analysis, using a computer program (GelPro Analyzer 3.0).
Mrp2 protein levels
Expression of Mrp2 was assessed by western blotting. For this purpose, samples of liver tissue were taken from multiple liver lobes immediately after perfusion with ice-cold saline, snap-frozen in liquid nitrogen, and stored at -70°C until assay.
Immunoblotting of Mrp2 was carried out on mixed membrane fractions, obtained as described by Meier et al. (1984) . Preparations were loaded onto 10% SDSpolyacrylamide gels and subjected to electrophoresis. After electrotransfer, nitrocellulose membranes were probed with a monoclonal, mouse anti-Mrp2 (MC-206; Kamiya Biomedical Co., Seattle, WA), at 1:2,000 dilution, for 1 h. The immune complex was detected by incubation with HRP-linked secondary antibodies (Amersham Pharmacia Biotech, Inc., Piscataway, NJ), at a 1:2,000 dilution, for 1 h.
Immunoreactive bands were detected using a chemiluminescence kit (ECL+Plus, Amersham Pharmacia Biotech, Inc), exposed to Bio-Max MR-2 films (Sigma Chemical Co.) for 5 minutes, and quantified by densitometry (Shimadzu CS-9000, Shimadzu Corporation, Kyoto, Japan).
Transport activity of Mrp2
Mrp2 transport activity was evaluated by administering CDNB (10 µmol per Kg of body weight, iv, in saline); CDNB permeates freely the sinusoidal membrane, and is further conjugated with GSH by the GST system, so that, its GSH derivate, dinitrophenyl-S-GSH (DNP-SG), is selectively excreted into bile by Mrp2. After CDNB administration, bile samples were collected at 10-min intervals for 60 min, and the biliary excretion rate of DNP-SG was calculated as the product of bile flow and the DNP-SG biliary concentration, as measured spectrophotometrically at 335 nm.
Statistical analysis
All the values were expressed as mean ± SE. Variables were statistically compared by the Student's t test. A value of p < 0.05 was considered significantly different.
RESULTS
After 90 days of Al treatment, no animal deaths occurred, and no evident toxic symptoms were observed in either Al (+) or Al (-) rats. At the end of the treatment, the mean body weight in Al (+) rats was not statistically different from that of non-treated rats [337 ± 4 g vs 335 ± 10 g in Al (+) and in Al (-) rats, respectively, p > 0.05]. An increase of Al levels in both plasma and liver was observed after the 90 days of Al administration. Plasma Al concentrations increased from 9 ± 4 µg/l (control rats) to 750 ± 50 µg/l, and the hepatic Al content augmented from 26 ± 9 µg per g of liver weight (control rats) to 122 ± 12 µg per g of liver weight.
The levels of lipid peroxidation in liver tissue and the status of hepatic antioxidant defenses following Al treatment are shown in Table 1 . Lipid peroxidation, as measured in terms of TBARS, was significantly increased in Al (+) rats. Contrarily, the total GSH content and the activities of the anti-oxidant enzymes, GST, GSH-Px and CAT were significantly reduced in Al (+) rats. Table 2 shows the basal bile flow and the basal excretion rate of different bile constituents after 90 days of Al treatment. Bile flow was decreased by 23% in Al (+) rats. Similarly, the biliary outputs of proteins, cholesterol and bile salts were significantly lower in Al (+) rats, as compared with those in Al (-) rats.
The efficiency of the different steps involved in the hepatic handling of the non-bile acid organic anion model, BSP, was assessed by pharmacokinetic analysis. Plasma decay of BSP was slower in Al (+) rats, as shown by the increase in the halt-times for de rapid and slow phases of plasma decay (Table 3) . Al treatment reduced significantly the plasma clearance of BSP (-59%), which was accompanied by a significant reduction in the fractional rate of hepatic BSP uptake (r 12 , -53%) and in the fractional rate of the biliary excretion of the dye (r 3, -43%). A clear tendency existed for the fractional rate of hepatic BSP reflux to be lower but, due to high interindividual variability, the difference did not achieve statistical significance (Table 3) .
The model organic anion, BSP, is selectively cleared by the liver, conjugated with GSH within the hepatocytes in a process catalyzed by a GST isoenzyme, and subsequently excreted into bile. Upon analyzing the biliary excretion of total, free and conjugated BSP, a decrease in the total excretion of the dye, without any change in the conjugated-to-total BSP ratio, was observed in Al (+) rats (Table 4) .
Since the canalicular transfer of BSP, the rate-limiting step in its overall transfer from plasma to bile, was significantly impaired by Al treatment, we assessed here both expression and function of Mrp2, the main canalicular carrier involved in this process.
Al induced a diminution in the Mrp2 levels (-40%), as quantified by densitometric analysis of the western blotting bands (Fig. 1) . Transport activity of this protein was further evaluated in vivo by analyzing the time-course of the biliary excretion of the Mrp2 substrate, DNP-SG. This substrate is produced intacellularly by GST-mediated conjugation with GSH of CDNB, which permeates freely the sinusoidal membrane; this avoids the influence of changes in basolateral transporter activity on its secretory process, so that its biliary excretion reflects either or both GST conjugating activity or Mrp2 transport efficiency. Fig 2 shows that Al treatment both reduced and delayed the biliary secretion of DNP-SG. As a consequence, both the peak of DNP-SG biliary excretion and its cumulative biliary secretion throughout the experimental period were both decreased by 50%, as compared with Al (-) groups.
Since GST conjugating activity towards CDNB was only diminished by 35% (see Table 1 ), changes in CDNB conjugation cannot be fully accounted for the decrease in DNP-SG output, the remaining drop been due to impaired transport activity.
DISCUSSION
The present study was performed to elucidate the mechanisms involved in the impairment of bile secretory function induced by chronic administration of Al to rats.
Exposure to Al for 3 months induced a significant ( 4-fold) increase in hepatic Al content, in line with previous studies where Al was administered parenterally (Bertholf et al., 1989; El-Maraghy et al., 2001) ; this finding was attributed to the presence of Al in hepatic giant cells (Bertholf et al., 1989) . The hepatic Al accumulation was accompanied with a decrease in bile flow and in bile salt secretion, a primary driving force for bile formation, suggesting that, at least in part, bile flow decrease was due to a reduction in its bile salt-dependent fraction. A similar finding was observed when Al was administered subchronically (i.e., during 14 days) (Klein et al., 1988) , but not when Al was given enterally, a fact attributed to lack of Al accumulation in liver under this administration manner (Klein et al., 1989b) . Our finding that bile secretory function was similarly affected 90 days after Al administration, as compared with a shorter administration period (14 days), indicates that no further compensatory mechanism takes place to counteract the alterations in the bile secretory mechanisms occurring early following Al exposure.
Whereas the alterations in the bile salt secretory function induced by Al intoxication had been evaluated previously (Klein et al., 1988) , no data are available in the literature on the changes induced by Al on the hepatic handling of non-bile salt organic anions. Its characterization is highly relevant, though, since these transport systems are involved in the biliary elimination of potentially toxic endo-and xenobiotics, including bilirubin, glucuronidated and sulfated bile salts, leukotriene C4, medicaments, and a number of dietary constituents (Takikawa, 2002; Klaassen, 2002) .
To determine possible alterations in these transport systems induced by Al administration, we evaluated the hepatic handling of the model organic anion, BSP, a relatively nontoxic organic anion, widely used as an indicator of liver function. For this purpose, kinetics analysis of the plasma disappearance of the dye, which provides a quantitative estimation of the efficiency by which transport events are functioning in the hepatocyte in vivo, was carried out. BSP is selectively taken up by the liver through a Na + -independent transport mechanism (mediated by the organic anion transporting polypeptide (OATP) families), conjugated with GSH within the hepatocytes by GST, and subsequently excreted into bile by the multispecific, ATPdependent canalicular transporter Mrp2 (Takikawa, 2002) . The pharmacokinetic analysis indicated that both sinusoidal uptake and canalicular excretion of the dye were impaired by Al administration, as assessed by the decrease in the fractional transfer rates for the transport of the dye from plasma to liver (r 12 ) and from liver to bile (r 3 ), respectively (see Table 3 ). The alteration in these transport steps, particularly the impairment in the canalicular transfer of the dye, which is the rate limiting step in the overall transfer of BSP from blood to bile, explains the decrease in the total excretion of the dye (see Table 4 ). Changes in BSP intrahepatic conjugation, a metabolic step which facilitates its canalicular transfer (Barnhart and Combes, 1976) seems not to account for the alteration of this transport step, as no change in the conjugated-to-total BSP ratio was observed in bile (see Table 4 ).
Although conjugating activity of GST, the enzyme involved in GSH-Sconjugation of the dye, was impaired by Al (see Table 1 ), increased transit time throughout the hepatocyte due to defective excretion, which increase chances for dye conjugation, may have compensated for the decrease in the conjugating activity. A differential effect of Al on transport efficiency of free and conjugated BSP cannot be however ruled out; for example, an impairment of bile salt output, like that occurring in Al-treated rats, may decrease selectively free BSP biliary output (Gregus et al., 1980) , thus explaining the lack of change in BSP output under conditions impaired BSP conjugation. Therefore, the alteration in the canalicular transfer of the dye is more likely accounted for by an alteration in the activity/content of its canalicular transporter, Mrp2. This contention was confirmed further by western blot analysis and the further assessment of functional activity of this transport protein. Indeed, the hepatic level of Mrp2 was decreased in Al (+) rats, which was accompanied by a decreased excretion of the specific Mrp2 substrate, DNP-SG.
The underlying mechanisms by which Al affects bile production in general, and organic anion transport status in particular, are far from being completely understood,
and cannot be addressed from our results. However, our results point to the possible involvement of oxidative stress in Al-induced hepatotoxicity (see Table 1 ), as indicated by an increase in TBARS, a finding causally linked to enhanced liver lipid peroxidation, and a decrease in the levels of anti-oxidant defenses, including reduced GSH and the antioxidant enzymes, CAT (Abubakar et al., 2003.) and GSH-Px (El-Maraghy et al.,
2001
). These results are in line with other studies showing that even lower ip Al doses, and shorter administration period than that used by us, induce a significant increase in hepatic reactive oxygen species (Abubakar et al., 2003.) , which is associated with a decreased level of hepatic anti-oxidant defenses, including reduced GSH (Abubakar et al., 2003.; El-Maraghy et al., 2001) , CAT (Abubakar et al., 2003.) , and GSH-Px (ElMaraghy et al., 2001) . Furthermore, the decrease in GST activity reported herein can be also a contributing factor, since this enzyme has GSH-Px activity and is instrumental in detoxifying lipid hydroperoxides (Mari and Cederbaum, 2001 ).
Oxidative stress alters expression of canalicular transporters at a posttranscriptional level, as a potential mechanism of alteration of biliary secretory function. Indeed, incorporation of oxidizing agents into the perfusate of the isolated, perfused rat liver leads to cholestasis, accompanied by loss of immunorective Mrp2 from the canalicular membrane due, in turn, to internalization of the transporter in subapical vesicles (Schmitt et al., 2000) . Sustained internalization as a consequence of long-lasting oxidative stress, likely to occur in our Al (+) rats, may lead to delivery of Mrp2 to the lysosomal compartment, followed by degradation, as was shown to occur late in lipopolysaccharide-induced cholestasis (Kubitz et al., 1999) . showing that Al (+) rats have an inhibited biliary excretion of protein and cholesterol, two compounds thought to reach bile mainly via a microtubule-dependent, vesicular mechanism (LaRusso, 1984; Marzolo et al., 1990) , make the first possibility likely.
However, a more direct action of Al in decreasing Mrp2 synthesis and/or in increasing Mrp2 degradation can not be excluded. Berlyne et al. (1972) proposed that Al exerts its hepatotoxic effect by affecting protein synthesis, a contention further confirmed by others showing that the hepatic levels of a number of phase I detoxifying enzyme proteins were shown to decrease after Al exposure (Fulton and Jeffery, 1994; Jeffery et al., 1987) . The reduction in the hepatic levels several enzymes reported in this study (see Table 1 ) confirms and extends this concept to phase II detoxifying enzymes (GST) and other anti-oxidant enzymes (CAT, GSH-Px). The second possibility, i.e., activation of lysosomal degradation of proteins by Al, seems more unlikely, since this metal was shown to inhibit rather than to activate the lysosomal proton pump (Zatta et al., 2000) . Irrespective of the mechanism involved, the impairment induced by Al in expression/function of Mrp2 and, presumably, of other transport proteins involved in transhepatocellular transport of cholephilic compound may explain, at least in part, the cholestatic effect of this metal. Indeed, Mrp2 mediates canalicular secretion of GSH (Paulusma et al., 1999) , a key determinant of the so called bile salt-independent fraction of the bile flow (Ballatori and Truong, 1992 ).
In conclusion, our results show that chronic Al intoxication induces cholestasis and impairs hepatic transport of organic anions by decreasing both sinusoidal uptake and canalicular excretion. This latter event, which is the rate-limiting step in the overall transport from plasma into bile, is accounted for by a decreased expression of the main transporter involved in this process, Mrp2. Clearly, additional investigations are needed to clarify the exact mechanism(s) through which Al exerts these deleterious effects.
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